Natco Pharma Q1 2023 Concall Highlights
Growth in revenue from operations – Q1FY23 vs Q1FY22 : ~115% Growth in export formulations – Q1FY23 vs Q1FY22 : ~400% Growth in domestic formulations – Q1FY23 vs Q1FY22 : ~ -56% Growth in Crop Health Sciences Division – Q1FY23 vs Q1FY22 : ~100% Cost of materials was much higher in the corresponding last quarter …